
Jürg Oliver Straub

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5908879/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmaceuticals and Personal Care Products in the Environment: What Are the Big Questions?. Environmental Health Perspectives, 2012, 120, 1221-1229.	2.8	1,033
2	Performance of an anaerobic membrane bioreactor for pharmaceutical wastewater treatment. Bioresource Technology, 2017, 229, 180-189.	4.8	88
3	Scienceâ€based Targets for Antibiotics in Receiving Waters from Pharmaceutical Manufacturing Operations. Integrated Environmental Assessment and Management, 2019, 15, 312-319.	1.6	86
4	Aquatic environmental risk assessment for human use of the old antibiotic sulfamethoxazole in Europe. Environmental Toxicology and Chemistry, 2016, 35, 767-779.	2.2	84
5	Use of acute and chronic ecotoxicity data in environmental risk assessment of pharmaceuticals. Environmental Toxicology and Chemistry, 2016, 35, 1201-1212.	2.2	80
6	A STRATEGY TO REDUCE THE NUMBERS OF FISH USED IN ACUTE ECOTOXICITY TESTING OF PHARMACEUTICALS. Environmental Toxicology and Chemistry, 2003, 22, 3031.	2.2	76
7	Exploiting monitoring data in environmental exposure modelling and risk assessment of pharmaceuticals. Environment International, 2014, 73, 176-185.	4.8	73
8	An environmental risk assessment for oseltamivir (Tamiflu®) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions. Ecotoxicology and Environmental Safety, 2009, 72, 1625-1634.	2.9	61
9	Environmental risk assessment of metformin and its transformation product guanylurea: II. Occurrence in surface waters of Europe and the United States and derivation of predicted no-effect concentrations. Chemosphere, 2019, 216, 855-865.	4.2	46
10	An Environmental Risk Assessment for Human-Use Trimethoprim in European Surface Waters. Antibiotics, 2013, 2, 115-162.	1.5	45
11	DETERMINISTIC AND PROBABILISTIC ACUTE-BASED ENVIRONMENTAL RISK ASSESSMENT FOR NAPROXEN FOR WESTERN EUROPE. Environmental Toxicology and Chemistry, 2007, 26, 795.	2.2	44
12	Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001. Toxicology Letters, 2002, 131, 137-143.	0.4	36
13	Environmental risk assessment of metformin and its transformation product guanylurea. I. Environmental fate. Chemosphere, 2019, 216, 844-854.	4.2	36
14	Combined Environmental Risk Assessment for 5-Fluorouracil and Capecitabine in Europe. Integrated Environmental Assessment and Management, 2007, preprint, 1.	1.6	30
15	Extending the environmental risk assessment for oseltamivir (Tamiflu®) under pandemic use conditions to the coastal marine compartment. Environment International, 2009, 35, 931-936.	4.8	30
16	A riskâ€based approach to managing active pharmaceutical ingredients in manufacturing effluent. Environmental Toxicology and Chemistry, 2016, 35, 813-822.	2.2	28
17	Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001. Toxicology Letters, 2002, 135, 231-237.	0.4	27
18	Concentrations of the UV filter ethylhexyl methoxycinnamate in the aquatic compartment: a comparison of modelled concentrations for Swiss surface waters with empirical monitoring data. Toxicology Letters, 2002, 131, 29-37.	0.4	26

JüRG OLIVER STRAUB

#	Article	IF	CITATIONS
19	Reduction in the environmental exposure of pharmaceuticals through diagnostics, Personalised Healthcare and other approaches. A mini review and discussion paper. Sustainable Chemistry and Pharmacy, 2016, 3, 1-7.	1.6	26
20	Mixture toxicity of the antiviral drug TamifluÂ $^{\odot}$ (oseltamivir ethylester) and its active metabolite oseltamivir acid. Aquatic Toxicology, 2010, 96, 194-202.	1.9	25
21	Environmental risk assessment for ancillary substances in biotechnological production of pharmaceuticals. Environmental Toxicology and Chemistry, 2012, 31, 681-687.	2.2	18
22	Environmental Risk Assessment for the Active Pharmaceutical Ingredient Mycophenolic Acid in European Surface Waters. Environmental Toxicology and Chemistry, 2019, 38, 2259-2278.	2.2	15
23	Combined environmental risk assessment for the antiviral pharmaceuticals ganciclovir and valganciclovir in Europe. Environmental Toxicology and Chemistry, 2017, 36, 2205-2216.	2.2	11
24	Recommendations on the Environmental Risk Assessment of Pharmaceuticals - Effect Characterization. Integrated Environmental Assessment and Management, 2007, preprint, 1.	1.6	9
25	Environmental risk assessment for excipients from galenical pharmaceutical production in wastewater and receiving water. Sustainable Chemistry and Pharmacy, 2015, 1, 28-35.	1.6	9
26	Protein and Peptide Therapeuticals: An Example of "Benign by Nature―Active Pharmaceutical Ingredients. , 2010, , 127-133.		7
27	Environmental Risk Assessment for Human Pharmaceuticals: The Current State of International Regulations. Emerging Topics in Ecotoxicology, 2012, , 17-47.	1.5	4
28	Rational selection of alternative, environmentally compatible surfactants for biotechnological production of pharmaceuticals-A step toward green biotechnology. Environmental Toxicology and Chemistry, 2014, 33, 2140-2146.	2.2	4
29	Erratum to "Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001―[Toxicol. Lett. 131(1–2) (2002) 137–143]. Toxicology Letters, 2002, 135, 229.	0.4	2